Insider Selling: Rapid Micro Biosystems (NASDAQ:RPID) CEO Sells 12,840 Shares of Stock

Rapid Micro Biosystems, Inc. (NASDAQ:RPID) CEO Robert Jr. Spignesi sold 12,840 shares of the business’s stock in a transaction that occurred on Monday, February 9th. The stock was sold at an average price of $3.78, for a total value of $48,535.20. Following the sale, the chief executive officer owned 962,097 shares of the company’s stock, valued at approximately $3,636,726.66. This trade represents a 1.32% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link.

Rapid Micro Biosystems Price Performance

RPID stock traded up $0.33 during midday trading on Tuesday, reaching $4.08. The stock had a trading volume of 306,371 shares, compared to its average volume of 371,737. The company’s fifty day simple moving average is $3.66 and its 200 day simple moving average is $3.39. The company has a market cap of $180.83 million, a price-to-earnings ratio of -4.04 and a beta of 1.38. The company has a current ratio of 4.23, a quick ratio of 2.95 and a debt-to-equity ratio of 0.42. Rapid Micro Biosystems, Inc. has a 52-week low of $1.86 and a 52-week high of $4.94.

Rapid Micro Biosystems (NASDAQ:RPID) last announced its quarterly earnings data on Friday, November 7th. The company reported ($0.26) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.26). The company had revenue of $7.84 million during the quarter, compared to analysts’ expectations of $7.60 million. Rapid Micro Biosystems had a negative net margin of 145.11% and a negative return on equity of 73.90%. As a group, sell-side analysts predict that Rapid Micro Biosystems, Inc. will post -1.1 earnings per share for the current fiscal year.

Analyst Ratings Changes

RPID has been the subject of several analyst reports. Weiss Ratings restated a “sell (d-)” rating on shares of Rapid Micro Biosystems in a report on Thursday, January 22nd. Wall Street Zen lowered shares of Rapid Micro Biosystems from a “hold” rating to a “sell” rating in a report on Saturday, January 17th. One equities research analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, Rapid Micro Biosystems has an average rating of “Moderate Buy” and an average target price of $8.00.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in RPID. Hudson Bay Capital Management LP acquired a new stake in Rapid Micro Biosystems during the 3rd quarter worth approximately $38,000. American Century Companies Inc. grew its stake in Rapid Micro Biosystems by 46.1% during the 2nd quarter. American Century Companies Inc. now owns 16,922 shares of the company’s stock worth $58,000 after buying an additional 5,341 shares during the last quarter. Nano Cap New Millennium Growth Fund L P purchased a new position in shares of Rapid Micro Biosystems during the fourth quarter worth approximately $72,000. XTX Topco Ltd purchased a new stake in shares of Rapid Micro Biosystems in the second quarter valued at about $144,000. Finally, Goldman Sachs Group Inc. acquired a new stake in shares of Rapid Micro Biosystems during the fourth quarter worth $160,000. Hedge funds and other institutional investors own 52.60% of the company’s stock.

Rapid Micro Biosystems Company Profile

Rapid Micro Biosystems (NASDAQ: RPID) develops and commercializes automated microbial detection and contamination control solutions for the life sciences industry. Its flagship offering, the Growth Direct® System, leverages digital imaging and proprietary growth indicator plates to identify and count microorganisms more rapidly than traditional culture-based methods. The company’s technology platform is designed to streamline quality control workflows in pharmaceutical, biotechnology and vaccine manufacturing settings, helping clients reduce release times and improve operational efficiency.

In addition to the Growth Direct® System, Rapid Micro Biosystems offers an integrated suite of software and consumables that support automated data capture, analysis and reporting.